On December 20, 2024 LaNova Medicines Ltd. reported the initiation of its first pivotal clinical trial for LM-108 (anti-CCR8 mAb) in China (Press release, LaNova Medicines, DEC 20, 2024, View Source [SID1234656019]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This clinical study (CTR20250219) is a Phase II, single-arm, multicenter, open-label trial primarily evaluating the efficacy and safety of LM-108 in combination with Toripalimab in patients with unresectable or metastatic MSI-H/dMMR advanced solid tumors who have failed prior treatment with anti-PD-1/PD-L1 therapies.